Premenstrual Dysphoric Disorder Awareness and Research Act of 2026
- Sponsor
- Rep. Ansari, Yassamin [D-AZ-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Mar 30, 2026
Bottom line
The bill seeks to improve understanding, diagnosis, and treatment of PMDD through enhanced research, public awareness, and professional training, with funding subject to future appropriations.
What it actually does
This bill aims to address Premenstrual Dysphoric Disorder (PMDD) by expanding federal research into its causes, diagnosis, and treatment, and supporting clinical trials. It mandates public health awareness campaigns and provider education to improve diagnosis and reduce stigma. Furthermore, it establishes a grant program to train health professionals in PMDD care and requires a report to Congress on the progress made.
Proponents argue
Supporters argue that PMDD is a debilitating and often misunderstood condition affecting millions, yet it remains under-diagnosed and under-researched. They contend that this bill is crucial for increasing public and provider awareness, reducing stigma, and fostering the development of effective treatments, thereby significantly improving the quality of life for affected individuals.
Opponents contend
Critics, if any, might express concerns about the open-ended 'such sums as is necessary' authorization for appropriations, suggesting it lacks fiscal discipline and could lead to unpredictable federal spending. They might also argue that existing federal health agencies already have the mandate to address such conditions, and a new, specific legislative directive might not be the most efficient approach.
The bill is concise and clearly written, making it accessible for a quick evaluation by an informed reader.
Section 3
PMDD Research and Data Collection
This section directs the National Institutes of Health (NIH) to expand and intensify research into Premenstrual Dysphoric Disorder (PMDD), covering its causes, risk factors, diagnosis, and treatment. It also mandates support for clinical trials to develop better treatment options and ensures diverse representation in PMDD research. Additionally, the Secretary of Health and Human Services is required to collect and publish data on PMDD prevalence, incidence, economic impact, and barriers to care.
Supporters argue
Proponents argue that dedicated research funding is essential to overcome the current knowledge gaps and develop effective interventions for PMDD, a condition that has historically been under-researched. They emphasize that data collection is vital for understanding the true scope and impact of PMDD.
Critics contend
No specific opposition is typically raised against expanding medical research, especially for under-studied conditions, as it is generally seen as a public good. Potential concerns might be about resource allocation within NIH's broader portfolio.
Tradeoffs
The primary tension is balancing the need for dedicated PMDD research with other competing health research priorities within the NIH budget. Ensuring adequate representation of diverse populations in research is a key consideration for equitable outcomes.
Section 4
PMDD Awareness and Provider Education
This section requires the Secretary of Health and Human Services to launch a public health awareness campaign. This campaign aims to educate patients and healthcare providers about PMDD symptoms and treatment options, reduce the stigma associated with menstrual health conditions, and encourage individuals to seek timely medical care. Furthermore, it directs the Health Resources and Services Administration (HRSA) to develop and distribute continuing medical education materials to ensure healthcare providers can accurately diagnose PMDD, differentiate it from other conditions, and provide evidence-based care.
Section 5
Grants for Health Professional Training
This section authorizes the Secretary to award grants to eligible entities, such as accredited medical schools, nursing schools, hospitals, and residency programs. These grants are intended to develop, establish, or expand training programs for various health professionals, including physicians, nurses, pharmacists, and social workers, to enhance their ability to provide care, treatment, and management services for PMDD. Additionally, it expands outreach activities to support training and opportunities for students and faculty in primary and specialty care services for mid-life women's health, including early detection, diagnosis, treatment, and care for perimenopause, menopausal symptoms, and related chronic conditions.
This subsection expands the scope of training opportunities beyond Premenstrual Dysphoric Disorder (PMDD) to include primary and specialty care services for 'mid-life women's health' and 'early detection, diagnosis, treatment, and care services for perimenopause, menopausal symptoms, and related chronic conditions.'
Section 5(e)
Why it matters:This inclusion might be a strategic move to broaden the bill's appeal and address a wider range of women's health concerns under the umbrella of a PMDD-focused bill, potentially making it more palatable to a wider coalition of supporters. It could also be seen as a natural extension of care for the same demographic.
Case for: Supporters would argue that mid-life women's health, perimenopause, and menopause are also significantly under-addressed areas in medical training and care. Integrating these into a broader women's health training initiative makes efficient use of resources and addresses multiple critical needs for the same patient population.
Case against: Critics might argue that broadening the scope could dilute the bill's primary focus on PMDD, potentially leading to less dedicated attention and resources for the specific disorder the bill is named after. It could also be seen as an attempt to pass broader policy changes under the guise of a more specific health initiative.
Estimated impact: Potentially expands the reach and impact of the training grants to a much larger segment of the female population, addressing a broader spectrum of reproductive and hormonal health issues beyond PMDD.